Publication | Closed Access

Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis

Healthcare ValueHealth EconomicsHealth PolicyClinical TrialsOutcomes ResearchClaims AnalysisPharmacoeconomicsHealth Care CostCost EffectivenessEconomic EvaluationMedicineTreated PatientHealth Services ResearchHealth Sciences